Cytotoxic activity of the infused Epstein-Barr virus-specific cytotoxic T-lymphocyte lines
| Patient . | Auto B-LCL . | Mismatched B-LCL . | Auto B-LCL + α class I . | Auto B-LCL + α class II . | Daudi cells . | Auto B-LCL CD4−effectors . | Auto B-LCL CD8− effectors . |
|---|---|---|---|---|---|---|---|
| 1 | 43 | 16 | 19 | 46 | ND | ND | ND |
| 2 | 49 | 18 | 21 | 51 | ND | ND | ND |
| 3 | 79 | 11 | 19 | ND | ND | ND | ND |
| 4 | 53 | 7 | 21 | 50 | ND | 45 | 263-150 |
| 5 | 35 | 9 | 8 | ND | 15 | ND | ND |
| 6 | 40 | 4 | 14 | 30 | ND | 22 | 35 |
| 7 | 36 | 14 | ND | ND | 10 | ND | ND |
| Patient . | Auto B-LCL . | Mismatched B-LCL . | Auto B-LCL + α class I . | Auto B-LCL + α class II . | Daudi cells . | Auto B-LCL CD4−effectors . | Auto B-LCL CD8− effectors . |
|---|---|---|---|---|---|---|---|
| 1 | 43 | 16 | 19 | 46 | ND | ND | ND |
| 2 | 49 | 18 | 21 | 51 | ND | ND | ND |
| 3 | 79 | 11 | 19 | ND | ND | ND | ND |
| 4 | 53 | 7 | 21 | 50 | ND | 45 | 263-150 |
| 5 | 35 | 9 | 8 | ND | 15 | ND | ND |
| 6 | 40 | 4 | 14 | 30 | ND | 22 | 35 |
| 7 | 36 | 14 | ND | ND | 10 | ND | ND |
Data are reported as the percentage of specific lysis at an effector-to-target ratio of 10:1. B-LCL, B-lymphoblastoid cell line; ND, not done.
A residual population of CD8dim + cells was present in the CD8− fraction.